Residual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated with neoadjuvant chemotherapy (NAC) had a higher score of a biomarker of distant metastatic recurrence than tumors from white patients, according to data presented at the 2022 San Antonio Breast Cancer Symposium, held December 6-10, 2022.
Racial disparity in pro-metastatic tumor microenvironment among women with residual breast cancer after NAC

Focused chemists in lab coats and safety goggles making experiments.
Comments